4'-Amino-5'-chloro-2'3'-ethylenedioxyacetophenone | 166816-09-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 4'-Amino-5'-chloro-2'3'-ethylenedioxyacetophenone
• 英文别名: 1-(8-Amino-7-chloro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethan-1-one；1-(5-amino-6-chloro-2,3-dihydro-1,4-benzodioxin-8-yl)ethanone
• CAS: 166816-09-7
• 化学式: C₁₀H₁₀ClNO₃
• 分子量: 227.647
• InChiKey: ZZJLMNFYILSVEI-UHFFFAOYSA-N

物化性质

• 沸点：
  421.8±45.0 °C(Predicted)
• 密度：
  1.387±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4'-Amino-5'-chloro-2'3'-ethylenedioxyacetophenone 生成 1-(4-amino-5-chloro-2,3-ethylenedioxyphenyl)-3-(pyridin-4-yl)propen-1-one
  参考文献：
  名称：

  1-phenylalkanone 5-HT.sub.4 receptor ligands

  摘要：

  本发明涉及新型5-HT.sub.4受体配体，其为1-(5-卤代-4-氨基苯基)(C.sub.2-6)烷基-1-酮衍生物，其中5-卤代-4-氨基苯基基团在其2位被(C.sub.1-4)烷氧基或苯基(C.sub.1-4)烷氧基取代，并且在其3位可选择地被(C.sub.1-4)烷氧基取代，或者在其2位和3位一起被亚甲二氧基或乙二氧基取代，而(C.sub.2-6)烷基-1-酮的最高编号碳被二(C.sub.1-4)烷基氨基、吗啉-1-基或吡咯烷-1-基取代，或者可选择地被取代的哌啶-1-基、哌啶-4-基、氮杂环庚-1-基、氮杂双环\x9b2.2.1!庚-3-基、氮杂双环\x9b2.2.2!辛-3-基或氮杂双环\x9b3.2.2!壬-3-基取代；以及这些衍生物的药学上可接受的盐、各个异构体和异构体混合物，以及使用和制备这种衍生物的方法。

  公开号：

  US05763458A1
• 作为产物：
  描述：

  6,7-dichlorobenzo-1,4-dioxane 在 aluminum (III) chloride 、 N-氯代丁二酰亚胺 、 palladium 10% on activated carbon 、 硝酸 、 potassium formate 、 溶剂黄146 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 115.5h， 生成 4'-Amino-5'-chloro-2'3'-ethylenedioxyacetophenone
  参考文献：
  名称：

  Process Development of the Synthetic Route to Sulamserod Hydrochloride

  摘要：

  Sulamserod hydrochloride is a potent 5-HT4 receptor antagonist and was a clinical candidate for the treatment of gastrointestinal disorders. Process development of the fairly long synthetic route (12 linear, 14 overall steps) was undertaken. Process improvements were highlighted by aromatic chlorination choices in making dichlorobenzodioxan 2 and acetylaminochloroketone 7, a transfer hydrogenation reducing a nitro group and simultaneous aromatic dechlorination without ketone reduction to give aminoketone 5, and use of the potential mutagenic iodosulfonamide 14 to make quaternary salt 11. The chemistry was scaled up into pilot plant reactor vessels to produce multikilogram amounts of Sulamserod hydrochloride suitable for drug development.

  DOI：

  10.1021/op0002040

文献信息

• [EN] NOVEL 1-PHENYLALKANONE 5-HT4 RECEPTOR LIGANDS<br/>[FR] NOUVEAUX LIGANDS 1-PHENYLALCANONE DU RECEPTEUR DE 5-HT4
  申请人：SYNTEX (U.S.A.) INC.

  公开号：WO1994027965A1

  公开（公告）日：1994-12-08

  (EN) The present invention relates to novel 5-HT4 receptor ligands which are 1-(5-halo-4-aminophenyl) (C2-6)alkan-1-one derivatives in which the 5-halo-4-aminophenyl group is substituted at its 2-position with (C1-4)alkyloxy or phenyl(C1-4)alkyloxy and optionally substituted at its 3-position with (C1-4)alkyloxy or substituted at its 2- and 3-positions together with methylenedioxy or ethylenedioxy and the highest numbered carbon of the (C2-6)alkan-1-one is substituted with di(C1-4)alkylamino, morpholin-1-yl or pyrrolidin-1-yl or optionally substituted piperidin-1-yl, piperidin-4-yl, azacyclohept-1-yl, azabicyclo[2.2.1]hept-3-yl, azabicyclo[2.2.2]oct-3-yl or azabicyclo[3.2.2]non-3-yl; and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers and methods of using and making such derivatives.(FR) L'invention concerne de nouveaux ligands du récepteur de 5-HT4 qui sont des dérivés de 1-(5-halo-4-aminophényl)(C2-6)alcane-1-one, dans lesquels le groupe 5-halo-4-aminophényle est substitué à sa position 2 par (C1-4)alkyloxy ou phényl(C1-4)alkyloxy et éventuellement substitué à sa position 3 par (C11-4)alkyloxy ou substitué à ses positions 2 et 3 par méthylènedioxy ou éthylènedioxy et le carbone à nombre le plus élevé de (C2-6)alcane-1-one est substitué par di(C1-4)alkylamino, morpholine-1-yl ou pyrrolidine-1-yle ou pipéridine-1-yle éventuellement substituée, pipéridine-4-yle, azacyclohept-1-yle, azabicyclo[2,2,1]hept-3-yle, azabicyclo[2,2,2]oct-3-yle ou azabicyclo[3,2,2]non-3-yle; sels pharmaceutiquement acceptables, isomères individuels et mélange d'isomères, ainsi que procédés d'utilisation et de préparation desdits dérivés.

  本发明涉及一种新型的5-HT4受体配体，其为1-(5-卤代-4-氨基苯基)(C2-6)烷基-1-酮衍生物，其中5-卤代-4-氨基苯基基团在其2位被取代为(C1-4)烷氧基或苯基(C1-4)烷氧基，且在其3位被取代为(C1-4)烷氧基或在其2位和3位被取代为亚甲二氧基或乙二氧基，而(C2-6)烷基-1-酮的最高编号碳被取代为二(C1-4)烷基氨基、吗啉-1-基或吡咯烷-1-基，或者是可选取代的哌啶-1-基、哌啶-4-基、氮杂环庚-1-基、氮杂双环[2.2.1]庚-3-基、氮杂双环[2.2.2]辛-3-基或氮杂双环[3.2.2]壬-3-基；以及这些衍生物的药学上可接受的盐、单一异构体和异构体混合物，以及制备和使用这些衍生物的方法。
• NOVEL 1-PHENYLALKANONE 5-HT 4? RECEPTOR LIGANDS
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0700383A1

  公开（公告）日：1996-03-13
• US5763458A
  申请人：——

  公开号：US5763458A

  公开（公告）日：1998-06-09
• 1-phenylalkanone 5-HT.sub.4 receptor ligands
  申请人：Syntex (U.S.A.) Inc.

  公开号：US05763458A1

  公开（公告）日：1998-06-09

  The present invention relates to novel 5-HT.sub.4 receptor ligands which are 1-(5-halo-4-aminophenyl) (C.sub.2-6)alkan-1-one derivatives in which the 5-halo-4-aminophenyl group is substituted at its 2-position with (C.sub.1-4)alkyloxy or phenyl(C.sub.1-4)alkyloxy and optionally substituted at its 3-position with (C.sub.1-4)alkyloxy or substituted at its 2- and 3-positions together with methylenedioxy or ethylenedioxy and the highest numbered carbon of the (C.sub.2-6)alkan-1-one is substituted with di(C.sub.1-4)alkylamino, morpholin-1-yl or pyrrolidin-1-yl or optionally substituted piperidin-1-yl, piperidin-4-yl, azacyclohept-1-yl, azabicyclo\x9b2.2.1!hept-3-yl, azabicylo\x9b2.2.2!oct-3-yl or azabicylo\x9b3.2.2!non-3-yl; and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers and methods of using and making such derivatives.

  本发明涉及新型5-HT.sub.4受体配体，其为1-(5-卤代-4-氨基苯基)(C.sub.2-6)烷基-1-酮衍生物，其中5-卤代-4-氨基苯基基团在其2位被(C.sub.1-4)烷氧基或苯基(C.sub.1-4)烷氧基取代，并且在其3位可选择地被(C.sub.1-4)烷氧基取代，或者在其2位和3位一起被亚甲二氧基或乙二氧基取代，而(C.sub.2-6)烷基-1-酮的最高编号碳被二(C.sub.1-4)烷基氨基、吗啉-1-基或吡咯烷-1-基取代，或者可选择地被取代的哌啶-1-基、哌啶-4-基、氮杂环庚-1-基、氮杂双环\x9b2.2.1!庚-3-基、氮杂双环\x9b2.2.2!辛-3-基或氮杂双环\x9b3.2.2!壬-3-基取代；以及这些衍生物的药学上可接受的盐、各个异构体和异构体混合物，以及使用和制备这种衍生物的方法。
• Process Development of the Synthetic Route to Sulamserod Hydrochloride
  作者：Bruce A. Kowalczyk、Robinson、John O. Gardner

  DOI：10.1021/op0002040

  日期：2001.3.1

  Sulamserod hydrochloride is a potent 5-HT4 receptor antagonist and was a clinical candidate for the treatment of gastrointestinal disorders. Process development of the fairly long synthetic route (12 linear, 14 overall steps) was undertaken. Process improvements were highlighted by aromatic chlorination choices in making dichlorobenzodioxan 2 and acetylaminochloroketone 7, a transfer hydrogenation reducing a nitro group and simultaneous aromatic dechlorination without ketone reduction to give aminoketone 5, and use of the potential mutagenic iodosulfonamide 14 to make quaternary salt 11. The chemistry was scaled up into pilot plant reactor vessels to produce multikilogram amounts of Sulamserod hydrochloride suitable for drug development.